The $15 billion ad-powered AI startup your doctor may already be using

OpenEvidence said nearly two-thirds of US doctors are using its AI-powered medical search engine, processing more than 42 million prompts last month. The Miami-based startup, founded in 2022, has reached a $15 billion valuation as doctors use its chatbot to search medical journals and clinical guidelines; its growing use is also prompting debate over the future of patient care.

Analysis

The investable question is whether clinician usage converts into a defensible, monetizable workflow—or remains a lightweight search habit. Prompt volume is not evidence of clinical reliance, retention, ad yield, or improved outcomes; the usage and physician-penetration claims need independent validation. If the product becomes a routine decision layer, it could pressure standalone medical-information products and give platforms such as Doximity or EHR vendors an incentive to bundle comparable tools. Conversely, verified citations and licensed content may strengthen the position of medical publishers such as Wolters Kluwer rather than displace them. The ads model is a material trust constraint: commercial influence in treatment discovery could trigger physician resistance, advertiser limits, or regulatory scrutiny, especially if recommendations are perceived as biased. Near term, the $15bn private valuation is not directly tradeable and may set an aggressive benchmark for health-AI peers. Over 1–3 months, watch for independently supported usage, retention, and monetization disclosures; over 6–18 months, the key test is integration into clinical workflows with evidence of safety and sustained use. Contrarian view: viral adoption may be real but economically weak if doctors use the tool episodically, while liability and content costs accrue before durable revenue does.

Key Decisions for Investors

• No direct position in OpenEvidence is available from the supplied information; avoid treating its private valuation or claimed adoption as a public-company earnings signal.
• Watch Doximity, EHR vendors, and medical-information publishers for product launches, bundling, or commentary that indicates substitution versus licensing demand. Do not trade the displacement thesis until usage, customer economics, or guidance shows measurable impact.
• Set an alert for independent evidence on active-user retention, ad monetization, content licensing, clinical accuracy, and workflow integration. A large gap between prompt counts and repeat use or paid adoption would weaken the valuation narrative.
• Falsifiers: credible evidence of sustained clinical workflow adoption and positive safety validation would support the platform thesis; a material accuracy incident, physician backlash to advertising, or restrictions on commercial influence would undermine it. No options trade is warranted without a public catalyst or measurable exposure.